AU2010223513B2 - Substituted 2-mercaptoquinoline-3-carboxamides as KCNQ2/3 modulators - Google Patents

Substituted 2-mercaptoquinoline-3-carboxamides as KCNQ2/3 modulators Download PDF

Info

Publication number
AU2010223513B2
AU2010223513B2 AU2010223513A AU2010223513A AU2010223513B2 AU 2010223513 B2 AU2010223513 B2 AU 2010223513B2 AU 2010223513 A AU2010223513 A AU 2010223513A AU 2010223513 A AU2010223513 A AU 2010223513A AU 2010223513 B2 AU2010223513 B2 AU 2010223513B2
Authority
AU
Australia
Prior art keywords
alkyl
methyl
carboxamide
quinoline
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010223513A
Other languages
English (en)
Other versions
AU2010223513A1 (en
Inventor
Gregor Bahrenberg
Achim Kless
Sven Kuhnert
Wolfgang Schroder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruenenthal GmbH
Original Assignee
Gruenenthal GmbH
Chemie Gruenenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40671387&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2010223513(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal GmbH, Chemie Gruenenthal GmbH filed Critical Gruenenthal GmbH
Publication of AU2010223513A1 publication Critical patent/AU2010223513A1/en
Application granted granted Critical
Publication of AU2010223513B2 publication Critical patent/AU2010223513B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/06Anti-spasmodics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2010223513A 2009-03-12 2010-03-11 Substituted 2-mercaptoquinoline-3-carboxamides as KCNQ2/3 modulators Ceased AU2010223513B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09003597 2009-03-12
EP09003597.3 2009-03-12
PCT/EP2010/001509 WO2010102811A1 (de) 2009-03-12 2010-03-11 Substituierte 2-mercaptochinolin-3-carboxamide als kcnq2/3 modulatoren

Publications (2)

Publication Number Publication Date
AU2010223513A1 AU2010223513A1 (en) 2011-11-03
AU2010223513B2 true AU2010223513B2 (en) 2014-12-04

Family

ID=40671387

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010223513A Ceased AU2010223513B2 (en) 2009-03-12 2010-03-11 Substituted 2-mercaptoquinoline-3-carboxamides as KCNQ2/3 modulators

Country Status (20)

Country Link
US (2) US20100234372A1 (https=)
EP (1) EP2406229A1 (https=)
JP (1) JP5727946B2 (https=)
KR (1) KR20110132590A (https=)
CN (1) CN102348692A (https=)
AR (1) AR075824A1 (https=)
AU (1) AU2010223513B2 (https=)
BR (1) BRPI1008939A2 (https=)
CA (1) CA2755004A1 (https=)
CL (1) CL2011002209A1 (https=)
CO (1) CO6410292A2 (https=)
EC (1) ECSP11011348A (https=)
IL (1) IL214945A0 (https=)
MX (1) MX2011009369A (https=)
NZ (1) NZ595625A (https=)
PE (1) PE20120790A1 (https=)
RU (1) RU2011141188A (https=)
TW (1) TWI461197B (https=)
WO (1) WO2010102811A1 (https=)
ZA (1) ZA201107444B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3178067B2 (ja) 1991-02-26 2001-06-18 ぺんてる株式会社 スズ−ニッケル二元合金電気めっき液組成物
TWI504395B (zh) * 2009-03-10 2015-10-21 Substituted 3-amino-2-mercaptoquinoline as a KCNQ2 / 3 modifier
BRPI1009428A2 (pt) * 2009-03-10 2016-03-01 Gruenenthal Gmbh 3-aminoisoxazolopiridina substituída como moduladores de kcnq2/3
TWI475020B (zh) 2009-03-12 2015-03-01 The substituted nicotine amide as a KCNQ2 / 3 modifier
TW201038565A (en) 2009-03-12 2010-11-01 Gruenenthal Gmbh Substituted 2-mercapto-3-aminopyridines as KCNQ2/3 modulators
SI2609086T1 (sl) 2010-08-27 2015-04-30 Gruenenthal Gmbh Substituirani 2-okso in 2-tiokso-dihidrokinolin-3-karboksamidi kot KCNQ2/3 modulatorji
DK2609083T3 (da) * 2010-08-27 2015-03-30 Gruenenthal Gmbh Substituerede 2-oxy-quinolin-3-carboxamider som KCNQ2/3 modulatorer
MX2013002295A (es) 2010-09-01 2013-05-09 Gruenenthal Gmbh 1-oxo-dihidroisoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
US9775843B2 (en) 2012-10-11 2017-10-03 Grünenthal GmbH Treatment and/or prophylaxis of TSPO mediated diseases and/or disorders
US9248122B2 (en) 2012-11-28 2016-02-02 Grünenthal GmbH Heteroquinoline-3-carboxamides as KCNQ2/3 modulators
AU2013351551A1 (en) 2012-11-28 2015-07-16 Grunenthal Gmbh Heteroquinoline-3-carboxamides as KCNQ2/3 modulators
BR112015012418A2 (pt) * 2012-11-28 2017-07-11 Gruenenthal Gmbh carboxamidas específicas como moduladores de kcnq2/3
CN105073738B (zh) * 2013-01-31 2018-01-05 沃泰克斯药物股份有限公司 作为钠通道调节剂的喹啉及喹喔啉酰胺类
US9139583B2 (en) 2013-02-01 2015-09-22 Acetylon Pharmaceuticals, Inc. Selective HDAC3 inhibitors
JP2016511237A (ja) 2013-02-01 2016-04-14 アセチロン ファーマシューティカルズ インコーポレイテッドAcetylon Pharmaceuticals,Inc. 選択的hdac3阻害剤
JP6669499B2 (ja) 2013-02-15 2020-03-18 カラ ファーマシューティカルズ インコーポレイテッド 治療用化合物
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
JP2016510000A (ja) 2013-02-20 2016-04-04 カラ ファーマシューティカルズ インコーポレイテッド 治療用化合物およびその使用
NZ719185A (en) 2013-11-01 2017-11-24 Kala Pharmaceuticals Inc Crystalline forms of therapeutic compounds and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
PH12015000236B1 (en) * 2015-07-06 2024-01-10 Samsung Electronics Co Ltd Electronic device for providing a calibrated keyboard configuration
AU2017324713B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
KR20190051010A (ko) 2016-09-08 2019-05-14 칼라 파마슈티컬스, 인크. 치료 화합물의 결정형 및 그의 용도
EP3509423A4 (en) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
EP3558992A4 (en) 2016-12-15 2020-12-02 ONO Pharmaceutical Co., Ltd. TREK CHANNEL ACTIVATOR (K + CHANNELS ASSOCIATED WITH TWIK)
DE102018212006B3 (de) * 2018-07-18 2019-10-31 Universität Greifswald Thioether als Modulatoren von Kv7.2/Kv7.3-Kanälen
JP2025529185A (ja) * 2022-08-30 2025-09-04 パンネックス セラピューティクス インコーポレイテッド パネキシン-1調節剤及びパネキシン-1が関与する疾患の治療方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008066900A1 (en) * 2006-11-28 2008-06-05 Valeant Pharmaceuticals International 1,4 diamino bicyclic retigabine analogues as potassium channel modulators

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2706977A1 (de) 1977-02-18 1978-08-24 Hoechst Ag Benzoesaeuren und deren derivate sowie verfahren zu ihrer herstellung
FR2532939A1 (fr) * 1982-09-13 1984-03-16 Roussel Uclaf Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2, leur preparation, leur application comme medicament, les compositions les renfermant et les nouveaux intermediaires obtenus
DE4032147A1 (de) 1990-10-10 1992-04-16 Bayer Ag Verwendung von substituierten 2-mercaptonicotinsaeurederivaten zur bekaempfung von endoparasiten, neue substituierte 2-mercaptonicotinsaeurederivate und verfahren zu ihrer herstellung
EP0716077A1 (de) 1994-12-08 1996-06-12 Ciba-Geigy Ag Aromatisch substituierte Omega-Aminoalkansäureamide und Alkansäurediamide und ihre Verwendung als Renininhibitoren
WO1996026925A1 (en) 1995-03-01 1996-09-06 Banyu Pharmaceutical Co., Ltd. Arylthioacetamide derivatives
DE19738615A1 (de) * 1997-09-04 1999-03-11 Clariant Gmbh Neue Lichtschutzmittel auf Basis von sterisch gehinderten Aminen
DE19738616A1 (de) 1997-09-04 1999-03-11 Clariant Gmbh 4-Hydroxychinolin-3-carbonsäure-Derivate als Lichtschutzmittel
JP2002534512A (ja) * 1999-01-15 2002-10-15 ノボ ノルディスク アクティーゼルスカブ 非ペプチドglp−1アゴニスト
NZ516610A (en) 1999-08-04 2004-05-28 Icagen Inc Benzanilides as potassium channel openers
NZ527771A (en) 1999-08-04 2005-04-29 Icagen Inc Methods for treating or preventing anxiety
US20020183335A1 (en) 2001-02-20 2002-12-05 Piyasena Hewawasam 2, 4-disubstituted pyrimidine-5-carboxamide derivatives as KCNQ potassium channel modulators
CA2438868A1 (en) * 2001-02-20 2002-09-19 Valentin K. Gribkoff Modulators of kcnq potassium channels and use thereof in treating migraine and mechanistically related diseases
US6593349B2 (en) 2001-03-19 2003-07-15 Icagen, Inc. Bisarylamines as potassium channel openers
AU2002256085A1 (en) * 2001-04-06 2002-10-21 Smithkline Beecham Corporation Quinoline inhibitors of hyak1 and hyak3 kinases
MXPA05002914A (es) 2002-09-17 2005-05-27 Pharmacia Corp Moduladores de los receptores x hepaticos aromaticos.
EP1585522B1 (en) 2002-12-23 2010-11-17 Icagen, Inc. Quinazolinones as potassium channel modulators
EP1449841A1 (en) 2003-02-19 2004-08-25 Bayer CropScience SA New fungicidal compounds
EP1680411A2 (en) 2003-10-08 2006-07-19 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters containing cycloalkyl or pyranyl groups
AP2006003769A0 (en) 2004-05-04 2006-10-31 Pfizer Ortho substituted aryl or heteroaryl amide compounds
RS56037B1 (sr) * 2004-06-24 2017-09-29 Vertex Pharma Modulatori atp-vezujućih kasetnih transportera
EP1814856A1 (en) 2004-11-12 2007-08-08 Galapagos N.V. Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes
EP1861394A1 (en) 2005-03-03 2007-12-05 H.Lundbeck A/S Substituted pyridine derivatives
DE102005038947A1 (de) 2005-05-18 2006-11-30 Grünenthal GmbH Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln
WO2007015767A1 (en) 2005-07-20 2007-02-08 Eli Lilly And Company Pyridine derivatives as dipeptedyl peptidase inhibitors
EP1922311A2 (en) 2005-09-09 2008-05-21 Brystol-Myers Squibb Company Acyclic ikur inhibitors
JP2009515934A (ja) 2005-11-18 2009-04-16 ノイロサーチ アクティーゼルスカブ 新規なキナゾリン誘導体及びこれらの医学的使用
WO2008011110A2 (en) 2006-07-20 2008-01-24 Amgen Inc. Di-amino-substituted heterocyclic compounds and methods of use
DE602007004638D1 (de) 2006-07-20 2010-03-18 Amgen Inc Benzoädüisoxazol-derivate als c-kit-tyrosinkinase-hemmer zur behandlung von erkrankungen im zusammenhang mit der überproduktion von histamin
WO2008012532A2 (en) 2006-07-27 2008-01-31 Astrazeneca Ab : pyridine-3-carboxamide compounds and their use for inhibiting 11-beta-hydroxysteroid dehydrogenase
DE102006049452A1 (de) 2006-10-17 2008-05-08 Grünenthal GmbH Substituierte Tetrahydropyrolopiperazin-Verbindungen und deren Verwendung in Arzneimitteln
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
AU2008285795A1 (en) 2007-08-03 2009-02-12 F. Hoffmann-La Roche Ag Pyridinecarboxamide and benzamide derivatives as TAAR1 ligands
CA2702469A1 (en) 2007-10-19 2009-04-23 Boehringer Ingelheim International Gmbh Ccr10 antagonists
TWI504395B (zh) * 2009-03-10 2015-10-21 Substituted 3-amino-2-mercaptoquinoline as a KCNQ2 / 3 modifier
BRPI1009428A2 (pt) * 2009-03-10 2016-03-01 Gruenenthal Gmbh 3-aminoisoxazolopiridina substituída como moduladores de kcnq2/3
TW201038565A (en) * 2009-03-12 2010-11-01 Gruenenthal Gmbh Substituted 2-mercapto-3-aminopyridines as KCNQ2/3 modulators
TWI475020B (zh) * 2009-03-12 2015-03-01 The substituted nicotine amide as a KCNQ2 / 3 modifier

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008066900A1 (en) * 2006-11-28 2008-06-05 Valeant Pharmaceuticals International 1,4 diamino bicyclic retigabine analogues as potassium channel modulators

Also Published As

Publication number Publication date
AR075824A1 (es) 2011-04-27
ECSP11011348A (es) 2011-10-31
US20120252841A1 (en) 2012-10-04
CO6410292A2 (es) 2012-03-30
KR20110132590A (ko) 2011-12-08
TWI461197B (zh) 2014-11-21
CN102348692A (zh) 2012-02-08
MX2011009369A (es) 2011-09-27
TW201034670A (en) 2010-10-01
RU2011141188A (ru) 2013-04-20
WO2010102811A1 (de) 2010-09-16
EP2406229A1 (de) 2012-01-18
BRPI1008939A2 (pt) 2016-03-15
CA2755004A1 (en) 2010-09-16
PE20120790A1 (es) 2012-07-08
ZA201107444B (en) 2012-06-27
NZ595625A (en) 2012-10-26
CL2011002209A1 (es) 2012-02-10
US20100234372A1 (en) 2010-09-16
JP2012520249A (ja) 2012-09-06
JP5727946B2 (ja) 2015-06-03
AU2010223513A1 (en) 2011-11-03
US8399673B2 (en) 2013-03-19
IL214945A0 (en) 2011-11-30

Similar Documents

Publication Publication Date Title
AU2010223513B2 (en) Substituted 2-mercaptoquinoline-3-carboxamides as KCNQ2/3 modulators
AU2010223511B2 (en) Substituted nicotinamides as KCNQ2/3 modulators
CN103209962B (zh) 作为kcnq2/3调节剂的取代的6-氨基-烟酰胺
AU2010223512B2 (en) Substituted 2-mercapto-3-aminopyridines as KCNQ2/3 modulators
AU2010223556B2 (en) Substituted 3-amino-2-mercaptoquinolines as KCNQ2/3 modulators
MX2013000748A (es) 2-amino-quinolina-3-carboxamidas sustituidas como moduladores de kcnq2/3.
CN103068804B (zh) 作为kcnq2/3调节剂的取代的2-氧基-喹啉-3-甲酰胺
WO2012025238A1 (en) Substituted quinoline-3-carboxamides as kcnq2/3 modulators
RS95003A (sr) Derivati aminohinolina i aminopiridina i njihova upotreba kao liganada adenozinskih a3 receptora
RS54002B1 (sr) Supstituisani 2-okso i 2-tiokso-dihidrohinolin-3-karboksamidi kao modulatori kcnq2/3
EP2611780A1 (en) Substituted 1-oxo-dihydroisoquinoline-3-carboxamides as kcnq2/3 modulators

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired